Literature DB >> 17538374

The Stockholm 20-year follow-up of aneurysmal subarachnoid hemorrhage outcome.

Göran Edner1, Håkan Almqvist.   

Abstract

OBJECTIVE: To assess the clinical and radiological long-term outcome after aneurysmal subarachnoid hemorrhage (SAH) in a defined referral area regarding recurrent SAH and de novo aneurysm formation.
METHODS: One hundred and two 1-year survivors after aneurysmal SAH, who were treated at the Neurosurgical Clinic, South Hospital, Stockholm, Sweden, between 1983 and 1985, were followed for 20 years. Forty-nine surviving patients were reevaluated. Hospital records and death certificates were scrutinized for all 53 nonsurviving patients. Clinical history penetration, Mini Mental Status, Rankin Disability Score, and Barthel Index were used to evaluate the outcome. Computed tomographic angiography was used to investigate the cerebral arteries.
RESULTS: One hundred and two patients were traced. Fifty-three patients were deceased. One patient had a hospital record of sustaining an aneurysmal SAH from a known but not clipped aneurysm. Three patients had nonaneurysmal intracerebral hemorrhage and two sustained traumatic SAH. There were 49 surviving patients. Six refused follow-up. None of these patients had hospital records of intracranial disease. Three of the 43 remaining patients could not be tested. None of the survivors had experienced a new SAH. Aneurysm base remnants were observed in 1% (eight patients, 790 person-years of follow-up) and de novo aneurysms were observed in 0.9% (seven patients, 790 person-years of follow-up).
CONCLUSION: From this epidemiological survey of patients with aneurysmal SAH, it was found that none of the patients experienced a recurrent subarachnoid bleed from the treated aneurysm during a 20-year follow-up period. Thus, a routine extreme long-term follow-up period is not necessary. De novo aneurysm formation and possible enlargements of aneurysm base remnants were observed in almost 2% of patients per person year and should, therefore, be subject of a routine, long-term follow-up.

Entities:  

Mesh:

Year:  2007        PMID: 17538374     DOI: 10.1227/01.NEU.0000255458.07140.E6

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  6 in total

1.  Long-term follow-up survey reveals a high yield, up to 30% of patients presenting newly detected aneurysms more than 10 years after ruptured intracranial aneurysms clipping.

Authors:  Michaël Bruneau; Michal Rynkowski; Karina Smida-Rynkowska; Jacques Brotchi; Olivier De Witte; Boris Lubicz
Journal:  Neurosurg Rev       Date:  2011-06-04       Impact factor: 3.042

2.  Clinical outcome and ischemic complication after treatment of anterior choroidal artery aneurysm: comparison between surgical clipping and endovascular coiling.

Authors:  B M Kim; D I Kim; Y S Shin; E C Chung; D J Kim; S H Suh; S Y Kim; S I Park; C S Choi; Y S Won
Journal:  AJNR Am J Neuroradiol       Date:  2007-11-16       Impact factor: 3.825

3.  Long-term prognosis in patients with clipped unruptured cerebral aneurysms--increased cerebrovascular events in patients with surgically treated unruptured aneurysms.

Authors:  Masaaki Hokari; Satoshi Kuroda; Naoki Nakayama; Kiyohiro Houkin; Tatsuya Ishikawa; Hiroyasu Kamiyama
Journal:  Neurosurg Rev       Date:  2013-04-19       Impact factor: 3.042

4.  Cause-specific mortality of 1-year survivors of subarachnoid hemorrhage.

Authors:  Miikka Korja; Karri Silventoinen; Tiina Laatikainen; Pekka Jousilahti; Veikko Salomaa; Jaakko Kaprio
Journal:  Neurology       Date:  2013-01-09       Impact factor: 9.910

5.  Repeated Aneurysm Intervention.

Authors:  Vladimír Beneš; Anna Štekláčová; Ondřej Bradáč
Journal:  Adv Tech Stand Neurosurg       Date:  2022

6.  Risk of recurrent subarachnoid haemorrhage, death, or dependence and standardised mortality ratios after clipping or coiling of an intracranial aneurysm in the International Subarachnoid Aneurysm Trial (ISAT): long-term follow-up.

Authors:  Andrew J Molyneux; Richard S C Kerr; Jacqueline Birks; Najib Ramzi; Julia Yarnold; Mary Sneade; Joan Rischmiller
Journal:  Lancet Neurol       Date:  2009-03-28       Impact factor: 44.182

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.